March 16 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O:
MONTE ROSA THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT TO SUPPORT PHASE 2 TRIAL EVALUATING MRT-2359 IN COMBINATION WITH APALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
MONTE ROSA THERAPEUTICS INC - TO INITIATE PHASE 2 STUDY OF MRT-2359 WITH APALUTAMIDE IN Q3 2026
MONTE ROSA THERAPEUTICS INC - ENTERS SUPPLY AGREEMENT WITH JOHNSON & JOHNSON FOR PHASE 2 MCRPC STUDY STARTING Q3 2026
MONTE ROSA THERAPEUTICS INC - TO CONDUCT AND SPONSOR TRIAL; JOHNSON & JOHNSON TO SUPPLY ERLEADA